On January 2, 2023, Buffalo Bills safety Damar Hamlin collapsed on the field at Paycor Stadium in Cincinnati after a tackle, his heart thrown into ventricular fibrillation by a blow that landed at the wrong instant in his cardiac cycle. Athletic trainers restored his heartbeat with a defibrillator within minutes. He survived, and within weeks he was walking out of the hospital. What almost no one outside cardiology discussed at the time was what came next for his heart, not the resuscitation, but the six to eight weeks afterward, when a heart that has been shocked back into rhythm is at its most electrically unstable and its most actively rewiring itself.
That rewiring period is not folklore among cardiologists. It has a name, a set of clinical trials behind it, and a set of guidelines that dictate exactly how long doctors wait before implanting a defibrillator in someone who has just survived a heart attack or cardiac arrest. Understanding why the heart needs that waiting period means understanding that a cardiac event does not simply damage tissue. It disrupts an electrical circuit built over a lifetime, and the heart spends the following weeks building a new one, not always successfully.
The Circuit That Gets Broken
A healthy heartbeat begins in the sinoatrial node, a cluster of specialized cells in the right atrium that fire spontaneously roughly sixty to one hundred times a minute, setting the pace for everything downstream. The signal spreads across the atria, pauses briefly at the atrioventricular node, then races down the His bundle and the Purkinje fibers, a conduction network engineered by evolution to make the ventricles contract in near-perfect unison. Cells pass this electrical signal to their neighbors through gap junctions, protein channels built largely from a molecule called connexin 43, which let ions flow directly from one cardiac cell into the next without waiting for a chemical messenger.
A heart attack interrupts a coronary artery, starving a patch of heart muscle of oxygen. Cells in that patch do not all die instantly. Some die within minutes, some over hours, and a ring of tissue around the dead core, cardiologists call it the border zone, survives in a chronically injured, electrically erratic state. Ion channels in the border zone misfire. Connexin 43 becomes patchy and disorganized. The result is a region of heart muscle that conducts electricity slower than normal and in unpredictable directions, which is exactly the substrate a reentrant arrhythmia needs: a signal that should have died out instead loops back on itself, firing the ventricles again and again, faster than the heart can pump blood. That is ventricular fibrillation, and it is what stopped Damar Hamlin’s heart.
Why the Danger Window Lasts Weeks, Not Days
The border zone does not stay in that unstable state forever, but it also does not stabilize overnight. Two major clinical trials shaped how cardiologists think about the timing of that instability. The DINAMIT trial, published in 2004, implanted defibrillators in high-risk heart attack survivors six to forty days after their event and found no survival benefit, in part because deaths from other causes offset any reduction in arrhythmic death. The IRIS trial, a similar European study, found the same pattern implanting even earlier, five to thirty-one days out. Both trials pointed to the same practical conclusion: implanting a defibrillator too early, while the heart is still actively remodeling, does not save lives the way doing it later does.
The heart doesn’t heal in a straight line. It rewires, and rewiring is unstable by definition.
Current American College of Cardiology and American Heart Association guidelines reflect that data directly: physicians generally wait at least forty days after a heart attack before implanting a permanent defibrillator for primary prevention, giving the border zone time to scar over and stabilize. During that waiting period, patients at high risk sometimes wear a LifeVest, a wearable cardioverter defibrillator made by Zoll Medical that can detect and treat sudden arrhythmias externally, buying time without committing to permanent hardware while the heart’s own repair process plays out.
Scar Tissue Is Not the Whole Story
Fibroblasts move into the damaged zone within days and begin laying down collagen, forming the scar that eventually replaces dead muscle. Scar tissue does not conduct electrical signals the way muscle does, so a mature scar is, in one sense, electrically inert and therefore safe: current has to route around it rather than through it. The danger sits in the weeks before that scar fully matures, when fibroblasts and surviving muscle cells exist side by side and can form partial, inconsistent electrical connections with each other. Work from researchers studying cardiac fibroblast-myocyte coupling has shown that fibroblasts can actually pass current to neighboring muscle cells under certain conditions, effectively wiring dead-end tissue into the conduction path and creating new opportunities for reentrant circuits.
The heart’s nervous system remodels on a similar, overlapping timescale. Peng-Sheng Chen, who studied cardiac autonomic remodeling first at Indiana University and later at Cedars-Sinai, documented a phenomenon called sympathetic nerve sprouting: after a heart attack, sympathetic nerve fibers grow densely into the border zone, a process driven partly by nerve growth factor released from injured tissue. That sprouting raises local norepinephrine levels unevenly across the heart, which makes some regions more electrically excitable than their neighbors. A heart with patchy, hyperactive sympathetic input is a heart primed for the kind of electrical chaos that produces sudden cardiac arrest weeks or months after the original event, not just in the first hours.
Targeting the Rewiring Process Instead of Just the Rhythm
Cardiac electrophysiologists have spent the last decade building therapies aimed directly at that autonomic remodeling rather than only at the arrhythmia it produces. Kalyanam Shivkumar, who directs the UCLA Cardiac Arrhythmia Center, and his colleague Olujimi Ajijola have mapped how the heart’s intrinsic nervous system, a dense web of neurons embedded in fat pads on the heart’s own surface, reorganizes after injury and how disrupting that reorganization can calm dangerous rhythms. Cardiac sympathetic denervation, a surgical procedure that removes the lower portion of the stellate ganglion feeding sympathetic fibers to the heart, has become a recognized rescue therapy for patients in electrical storm, a state of repeated, closely spaced ventricular arrhythmias that standard defibrillator shocks alone cannot control.
Sudden cardiac arrest is not a single event. It’s a window that can reopen for weeks.
Vagus nerve stimulation has followed a rockier path toward the same goal. The ANTHEM-HF and INOVATE-HF trials tested whether stimulating the vagus nerve, which carries the parasympathetic signals that counterbalance sympathetic overdrive, could improve outcomes in heart failure patients whose hearts had already undergone this kind of adverse remodeling. INOVATE-HF, a larger trial sponsored by BioControl Medical, did not meet its primary endpoint, a reminder that dialing a single nerve is a blunter instrument than cardiologists once hoped, even when the underlying biology, an imbalance between sympathetic and parasympathetic tone in a remodeled heart, is well established.
The Hardware Built Around a Moving Target
Device design has adapted to the same timeline. A defibrillator implanted too early competes with a heart that is still finding its new electrical footing, while a defibrillator implanted too late leaves a patient exposed during the most volatile weeks. The devices below represent different answers to that problem, from bridging therapy to long-term implants.
| Device | Maker | Role in the remodeling window | Milestone |
|---|---|---|---|
| LifeVest | Zoll Medical | External bridge during the 40-day post-MI waiting period | FDA cleared, widely used since the early 2000s |
| S-ICD (subcutaneous ICD) | Boston Scientific | Long-term protection without leads touching the heart itself | FDA approved, 2012 |
| Micra leadless pacemaker | Medtronic | Pacing support without a transvenous lead crossing the healing border zone | FDA approved, 2016 |
| CardioMEMS | Abbott | Monitors pressure changes as remodeling affects heart failure status | FDA approved, 2014 |
The subcutaneous ICD matters here for a specific reason: because its lead sits under the skin rather than threading into the heart itself, it avoids adding another piece of hardware to a border zone that is already electrically busy rewiring itself. The leadless Micra pacemaker follows the same logic in miniature, replacing a wire that would otherwise sit against irritated, remodeling tissue with a self-contained capsule fixed directly to the ventricular wall.
What Counts as Healed
Cardiologists no longer treat the weeks after a heart attack as a simple countdown to recovery. They treat it as a distinct physiological state, a period in which fibroblasts, sprouting nerve fibers, and surviving muscle cells are all negotiating a new electrical arrangement in real time, and in which that negotiation can fail in ways that kill a patient who otherwise looks like they are getting better. The forty-day rule embedded in ICD guidelines is not an arbitrary bureaucratic delay. It is a number derived from watching what happens when doctors intervene before that negotiation finishes.
The open question for the field is whether therapies aimed at the remodeling process itself, sympathetic denervation, more precisely targeted neuromodulation, drugs that slow fibroblast-driven electrical coupling, can shrink that dangerous window rather than simply protecting patients through it. Damar Hamlin’s heart, like every heart that survives a cardiac event, spent weeks quietly rebuilding a circuit that took decades to establish the first time. Medicine’s job now is deciding how much of that rebuilding to trust, and how much to interrupt.
Credit: Natanael Melchor on Unsplash